About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Group 1 - The buy-and-hold investment strategy is advantageous as it simplifies investing, reduces exposure to market volatility, limits fees and taxes, and benefits from compounding, especially when dividends are reinvested [1] - Abbott Laboratories is highlighted as a strong candidate for long-term investment due to its stability and growth potential in the healthcare sector [2][3] Group 2 - Abbott Laboratories is a well-established leader in the medical device industry, with a strong reputation and established relationships with healthcare professionals, providing a competitive advantage [5] - The company demonstrates a strong innovative capacity, with industry-leading products such as the MitraClip and Amplatzer Occluder devices, which address specific medical needs through minimally invasive techniques [6] - Abbott's FreeStyle Libre continuous glucose monitoring systems are recognized as a significant advancement in diabetes management, achieving record sales and showcasing the company's ability to generate robust financial results [7][8]

Core Insights - Abbott reported quarterly earnings of $1.3 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.21 per share a year ago [1] - The company posted revenues of $11.37 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.24%, but up from $10.64 billion year-over-year [2] - Abbott's shares have increased by approximately 17.8% year-to-date, outperforming the S&P 500's gain of 13% [3] Earnings Performance - Over the last four quarters, Abbott has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $1.49, with expected revenues of $11.75 billion, and for the current fiscal year, the estimate is $5.15 on revenues of $44.66 billion [7] Market Outlook - The sustainability of Abbott's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Abbott is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Products industry, to which Abbott belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

格隆汇10月15日｜医疗设备制造商雅培公布第三季度业绩，营收为113.7亿美元，略低于分析师平均预 期的114亿美元；每股收益为1.3美元，符合分析师预期。雅培预计全年每股收益将介于5.12至5.18美元 之间，之前预期为5.1至5.2美元。 ...

THIRD-QUARTER 2025 RESULTS $5.4B MEDICAL DEVICES $1.5B ESTABLISHED $2.2B NUTRITION $5.12 to $5.183 REAFFIRMED FULL-YEAR GUIDANCE TOTAL COMPANY SALES $11.4B +7.5%1 Organic* sales growth for underlying base business** ADJUSTED DILUTED EPS $1.302 KEY BUSINESS UNITS ADJUSTED DILUTED EPS Narrowed range reflects double-digit growth at the midpoint 7.5% to 8.0%3 ORGANIC SALES GROWTH Excluding COVID-19 testing-related sales BUSINESS HIGHLIGHTS EXPANDING ALTERNATIVES TO OPEN-HEART SURGERY EXTENDING GLOBAL REACH OF S ...

Core Viewpoint - Abbott's quarterly revenue fell short of Wall Street expectations due to weak performance in its diagnostics and nutrition segments, despite strong demand for its medical device products [1][2] Financial Performance - Abbott reported third-quarter revenue of approximately $11.37 billion, slightly below the average analyst expectation of $11.40 billion [1] - The company's adjusted earnings per share for Q3 were $1.30, in line with Wall Street's average forecast [2] - Abbott now expects full-year adjusted earnings per share to be in the range of $5.12 to $5.18, down from the previous range of $5.10 to $5.20, reflecting uncertainties from tariffs and regulatory policies [2] Business Segment Analysis - The diagnostics division, which includes sales of COVID-19 and diabetes testing products, saw an unexpected decline of 6.6% to $2.25 billion, below the average analyst expectation of $2.29 billion [1] - In contrast, the medical devices segment experienced a robust growth of 14.8%, reaching $5.45 billion, driven by strong demand for continuous glucose monitoring devices and advanced cardiac equipment [1] Industry Context - The healthcare sector is facing challenges from the normalization of demand post-COVID-19 and regulatory headwinds from the Trump administration's freeze on external economic aid [1] - Abbott's performance issues are attributed more to product mix and cyclical normalization rather than a collapse in demand [2]

Market Overview - US stock index futures are all up, with Dow futures rising by 0.56%, S&P 500 futures up by 0.76%, and Nasdaq futures increasing by 0.99% [1] - European indices show mixed results, with Germany's DAX up by 0.02%, UK's FTSE 100 down by 0.38%, France's CAC40 up by 2.30%, and the Euro Stoxx 50 up by 1.28% [2][3] - WTI crude oil prices increased by 0.73% to $59.13 per barrel, while Brent crude rose by 0.51% to $62.71 per barrel [3][4] Federal Reserve Insights - Federal Reserve Chairman Jerome Powell hinted at a potential 25 basis point rate cut later this month, despite the government shutdown affecting economic assessments [5] - Powell emphasized ongoing risks in the labor market, noting a slowdown in hiring that could worsen [5] Commodity Market Reactions - Following Powell's dovish remarks, copper prices rebounded, with industry insiders predicting prices could reach $12,000 per ton [5] Economic Data Concerns - The ongoing government shutdown raises concerns about the accuracy of the upcoming October Consumer Price Index (CPI) data, as the Labor Statistics Bureau has been unable to collect new price information since the shutdown began [6] - Morgan Stanley's David Kelly warned that the US is "slowly heading towards bankruptcy," with national debt exceeding $37.8 trillion and interest payments surpassing $1.2 trillion [6] Company Earnings Reports - Morgan Stanley reported Q3 net revenue of $18.22 billion, an 18% year-over-year increase, exceeding expectations [7] - Abbott's Q3 revenue was approximately $11.37 billion, slightly below analyst expectations due to weak performance in its diagnostics and nutrition segments [7] - Dollar Tree projected a 12-15% annual growth in earnings per share over the next three years, with a near 20% growth expected in FY2026 [8] - Bank of America reported Q3 earnings exceeding expectations, driven by a resurgence in merger and acquisition activity, with net interest income also surpassing forecasts [9] - ASML's Q3 orders exceeded expectations, driven by strong demand in the AI infrastructure sector, with orders reaching €5.4 billion (approximately $6.3 billion) [9] - Apple's Q3 shipments in China grew by 0.6% year-over-year, reaching 10.8 million units, despite a declining overall smartphone market [10] - Eli Lilly's oral weight-loss drug orforglipron showed promising results in clinical trials, with plans to apply for market approval next year [11]

Core Insights - Abbott Laboratories reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales, slightly missing sales expectations of $11.39 billion [1][2] - The company reaffirmed its sales guidance for 7.5% to 8% organic sales growth for the year, excluding the impact of Covid tests, and narrowed its earnings outlook to a range of $5.12 to $5.18 per share [2] Financial Performance - In the same quarter last year, Abbott earned $1.21 per share on $10.64 billion in sales, indicating a year-over-year earnings increase of approximately 7.4% and sales growth of about 6.9% [2] - Analysts projected an average earnings per share of $5.15 and total sales of $44.69 billion for the year [2] Stock Market Reaction - In premarket trading, Abbott's stock fell nearly 3% to $128.94, breaking out of a cup-with-handle base with a buy point at $134.71 [3] - The stock is currently below the 5% chase zone and facing resistance at its 50-day moving average [3]

Core Insights - Abbott missed analysts' estimates for third-quarter revenue, reporting total revenue of $11.37 billion, slightly below the expected $11.40 billion, leading to a 3% drop in shares premarket [1][2]. Revenue Breakdown - Diagnostics segment sales fell 6.6% to $2.25 billion, missing the estimate of $2.29 billion, primarily due to a decline in COVID-19 testing demand [3]. - Medical devices segment sales increased 14.8% to $5.45 billion, driven by strong demand for continuous glucose monitors and heart devices [3]. External Factors - The halt of foreign aid has disrupted the supply chain for medical products and diagnostic tests in low-income countries, impacting Abbott's operations [2]. - Abbott is facing pricing pressure from China's procurement program, which purchases medical devices in bulk at significant discounts [2]. Profitability - On an adjusted basis, Abbott reported a third-quarter profit per share of $1.30, aligning with analysts' expectations [4]. - The company revised its annual adjusted profit forecast to a range of $5.12 to $5.18 per share, slightly down from the previous range of $5.10 to $5.20 [4].

The company narrowed its guidance for the second time this year. ...